Oct 16 (Reuters) – KEXING BIOPHARM: * KEXING BIOPHARM: CO'S BIOLOGICS LICENSE APPLICATION FOR LONG-ACTING G-CSF CANDIDATE GB-K02 ACCEPTED FOR REVIEW Source text:
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Oct 16 (Reuters) - Chinese online retailer Temu has agreed to settle data privacy claims…
Martinez available for Leeds trip after Man United criticism, Carrick says
VIDEO SHOWS: RECENT MANCHESTER UNITED TRAINING FOOTAGE WITH FOCUS ON DEFENDER LISANDRO MARTINEZ / PRESS…
ANALYSIS-SpaceX's spectrum deal still leaves it far from rivaling telecom giants
* SpaceX agrees to buy Grain's nationwide 800 MHz portfolio for about $8 billion, a…
